Inhibition of all-TRANS-retinoic acid metabolism by R116010 induces antitumour activity
- PMID: 11870544
- PMCID: PMC2375285
- DOI: 10.1038/sj.bjc.6600056
Inhibition of all-TRANS-retinoic acid metabolism by R116010 induces antitumour activity
Abstract
All-trans-retinoic acid is a potent inhibitor of cell proliferation and inducer of differentiation. However, the clinical use of all-trans-retinoic acid in the treatment of cancer is significantly hampered by its toxicity and the prompt emergence of resistance, believed to be caused by increased all-trans-retinoic acid metabolism. Inhibitors of all-trans-retinoic acid metabolism may therefore prove valuable in the treatment of cancer. In this study, we characterize R116010 as a new anticancer drug that is a potent inhibitor of all-trans-retinoic acid metabolism. In vitro, R116010 potently inhibits all-trans-retinoic acid metabolism in intact T47D cells with an IC(50)-value of 8.7 nM. In addition, R116010 is a selective inhibitor as indicated by its inhibition profile for several other cytochrome P450-mediated reactions. In T47D cell proliferation assays, R116010 by itself has no effect on cell proliferation. However, in combination with all-trans-retinoic acid, R116010 enhances the all-trans-retinoic acid-mediated antiproliferative activity in a concentration-dependent manner. In vivo, the growth of murine oestrogen-independent TA3-Ha mammary tumours is significantly inhibited by R116010 at doses as low as 0.16 mg kg(-1). In conclusion, R116010 is a highly potent and selective inhibitor of all-trans-retinoic acid metabolism, which is able to enhance the biological activity of all-trans-retinoic acid, thereby exhibiting antitumour activity. R116010 represents a novel and promising anticancer drug with an unique mechanism of action.
Figures
![Figure 1](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a05c/2375285/b102a6220374/86-6600056f1.gif)
![Figure 2](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a05c/2375285/f27c0ba639ad/86-6600056f2.gif)
![Figure 3](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a05c/2375285/21c543215a07/86-6600056f3.gif)
![Figure 4](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a05c/2375285/4f59493f9617/86-6600056f4.gif)
![Figure 5](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a05c/2375285/1dba303df088/86-6600056f5.gif)
![Figure 6](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a05c/2375285/63ac65830dd6/86-6600056f6.gif)
Similar articles
-
Molecular targeting of retinoic acid metabolism in neuroblastoma: the role of the CYP26 inhibitor R116010 in vitro and in vivo.Br J Cancer. 2007 Jun 4;96(11):1675-83. doi: 10.1038/sj.bjc.6603779. Epub 2007 May 8. Br J Cancer. 2007. PMID: 17486130 Free PMC article.
-
Increasing the intracellular availability of all-trans retinoic acid in neuroblastoma cells.Br J Cancer. 2005 Feb 28;92(4):696-704. doi: 10.1038/sj.bjc.6602398. Br J Cancer. 2005. PMID: 15714209 Free PMC article.
-
Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice.J Med Chem. 2004 Dec 30;47(27):6716-29. doi: 10.1021/jm0401457. J Med Chem. 2004. PMID: 15615521
-
Cytochrome p450 retinoic acid 4-hydroxylase inhibitors: potential agents for cancer therapy.Mini Rev Med Chem. 2002 Jun;2(3):261-9. doi: 10.2174/1389557023406223. Mini Rev Med Chem. 2002. PMID: 12370067 Review.
-
The cloning and characterization of a novel cytochrome P450 family, CYP26, with specificity toward retinoic acid.Nutr Rev. 1998 Mar;56(3):84-5. doi: 10.1111/j.1753-4887.1998.tb01699.x. Nutr Rev. 1998. PMID: 9564181 Review.
Cited by
-
Therapeutic potential of the inhibition of the retinoic acid hydroxylases CYP26A1 and CYP26B1 by xenobiotics.Curr Top Med Chem. 2013;13(12):1402-28. doi: 10.2174/1568026611313120004. Curr Top Med Chem. 2013. PMID: 23688132 Free PMC article. Review.
-
Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth.Br J Cancer. 2007 Apr 23;96(8):1204-15. doi: 10.1038/sj.bjc.6603705. Epub 2007 Mar 27. Br J Cancer. 2007. PMID: 17387344 Free PMC article.
-
Cu(ii)-catalyzed C-N coupling of 2-aminobenzothiazoles with boronic acids at room temperature.RSC Adv. 2023 Jun 8;13(25):17188-17193. doi: 10.1039/d3ra02979d. eCollection 2023 Jun 5. RSC Adv. 2023. PMID: 37304782 Free PMC article.
-
Molecular targeting of retinoic acid metabolism in neuroblastoma: the role of the CYP26 inhibitor R116010 in vitro and in vivo.Br J Cancer. 2007 Jun 4;96(11):1675-83. doi: 10.1038/sj.bjc.6603779. Epub 2007 May 8. Br J Cancer. 2007. PMID: 17486130 Free PMC article.
-
Liposomal delivery of hydrophobic RAMBAs provides good bioavailability and significant enhancement of retinoic acid signalling in neuroblastoma tumour cells.J Drug Target. 2020 Jul;28(6):643-654. doi: 10.1080/1061186X.2019.1710157. Epub 2020 Jan 14. J Drug Target. 2020. PMID: 31903789 Free PMC article.
References
-
- AchkarCCBentelJMBoylanJFScherHIGudasLMillerJrWH1994Differences in the pharmacokinetic properties of orally administered all-trans-retinoic acid and 9-cis-retinoic acid in the plasma of nude mice Drug Metab Dispos 22451458 - PubMed
-
- BruynseelsJDe CosterRVan RooyPWoutersWCoeneM-CSnoeckERaeymaekersAFreyneESanzGVanden BusscheGVanden BosscheHWillemsensGJanssenPAJ1990R75251, a new inhibitor of steroid biosynthesis Prostate 16345357 - PubMed
-
- DijkmanGAVan MoorselaarRJAVan GinckelRVan StratumPWoutersLDebruyneFMJSchalkenJADe CosterR1994Antitumoral effects of liarozole in androgen-dependent and -independnet R3327-Dunning prostate adenocarcinomas J Urol 151217222 - PubMed
-
- GarrabrantTAEndDW1995A rapid assay for measuring the metabolism of [3H]-retinoic acid in cell cultures J Pharmacol Toxicol Meth 34219223 - PubMed
-
- HanISChoiJ-H1996Highly specific cytochrome P450-like enzymes for all-trans-retinoic acid in T47D human breast cancer cells J Clin Endocrinol Metab 8120692075 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources